---
title: "GI Stromal Tumors"
format: 
  revealjs:
    slide-number: c/t
    width: 1600
    height: 900
    logo: "atriumlogo.jpg"
    footer: "[GI Surgical Oncology Talks](https://gisurgonc.github.io/talks/)"
    #css: ["theme/theme.css"]
    theme: default
      
    echo: false
editor: visual
bibliography: zotero.bib
---

## ACOSOG ZZ9001

GIST Tumors \>3cm randomized:

-   1 year of imatinib 40mg
-   Observation

Recurrence-free survival 98% vs 83%

No significant difference at 6 years

*Imatinib may simply delay recurrences*

::: aside
Ref
:::

## SSG SVII

High-risk GIST randomized:

-   1 year of imatinib 400mg
-   3 year of imatinib 400mg

5-year Recurrence-free survival 48% vs 66%

5-year Overall Survival 82% vs 92%

::: aside
Ref
:::

## Mutational Testing

Genetic mutations can predict response to imatinib [^1]

[^1]: Meheran JCO 2017

## Positive Margins

::: aside
Gronchi JAMA Surg 2020
:::

## Imatinib 1yr vs 3 yr

::: aside
Joensuu JAMA Oncology 2020
:::

## Wild-Type GIST

-   SDH-Deficient
    -   SDHx mutation
    -   SDH wild-type
    -   Associated with Carney-Stratakis syndrome
-   No SDH Deficiency
    -   NF1-GIST
    -   Sporadic Wild-Type GIST

::: aside
Weldon JCS 2017
:::

## NF1-associated GIST

-   Multicentric (33%)
-   Median age 46
-   Small bowel \>\> Duodenum \>\> Stomach

::: aside
Weldon JCS 2017
:::

## Recurrence Risk

+-------------------+-------------+--------------+
| Risk              | Size        | Mitotic Rate |
+===================+=============+==============+
| Very Low Risk     | \<2cm       | \<5          |
+-------------------+-------------+--------------+
| Low Risk          | 2-5cm       | \<5          |
+-------------------+-------------+--------------+
| Intermediate Risk | \<5cm\      | 6-10\        |
|                   | 5-10cm      | \<5          |
+-------------------+-------------+--------------+
| High Risk         | \>5cm\      | \>5 /50\     |
|                   | \>10cm\     | Any\         |
|                   | Any size    | \>10         |
+-------------------+-------------+--------------+

: Mitotic rate per 50 hpf

::: aside
Fletcher Int J Surg Pathol 10:81 2022
:::

## AFIP Risk Classification


+-----------+----------------+------------------+----------------+-------------------+---------------+
| **Group** | **Size**       | **Mitotic rate** | **Gastric**    | **Jejunal/Ileum** | **Duodenal**  |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 1         | ≤ 2 cm\*\*     | ≤ 5 per 50 hpf   | None (0%)      | None (0%)         | None (0%)     |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 2         | \>2 ≤ 5 cm     |      "           | Very Low (1.9%)| Low (4.3%)        | Low (8.3%)    |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 3a        | \> 5 ≤ 10 cm   |      "           | Low (3.6%)     | Moderate (24%) ǂ  | High† (34%) ǂ |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 3b        | \> 10 cm       |      "           | Moderate (12%) |  High (52%)       |               |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 4         | ≤ 2 cm         |  \> 5 per 50 hpf | None†.         |  High (50%)       |  §            |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 5         | \> 2 cm ≤ 5 cm |      "           | Moderate (16%) |  High (73%)       |  High (50%)    |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 6a        | \> 5 cm ≤ 10cm |      "           | High (52%)     |  High (85%)       |  High (86%)ǂ  |
+-----------+----------------+------------------+----------------+-------------------+---------------+
| 6b        | \> 10 cm       |      "           | High (86%)     |  High (90%)       |               |
+-----------+----------------+------------------+----------------+-------------------+---------------+


::: aside
Miettinen Lasota Seminars in Diagnostic Pathology 2006:23:70-83
:::

# Orientation Manual

{{< qrcode https://gisurgonc.github.io/orientation width=500 height=500 >}}

# References
